MedTrace Logo

EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

NCT01756248 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3872

Last updated 2023-06-07

No results posted yet for this study

Summary

This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).

The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice.

A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.

Conditions

  • Macular Degeneration

Interventions

DRUG

Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)

Patients treated with EYLEA under practical manner for AMD.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-26
Primary Completion
2018-12-31
Completion
2019-05-20

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01756248 on ClinicalTrials.gov